Grant Income	3 Months Ended
Mar. 31, 2022
Grant Income
Grant Income	(4) Grant Income In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $0 and $29,340 for the three months ended March 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $0 and $29,340 during the three months ended March 31, 2022 and 2021, respectively. The Company recorded a grant receivable of $0 as of March 31, 2022 and December 31, 2021, and had no unreimbursed, eligible costs incurred under the grant. As of March 31, 2022, there were no remaining funds available under the grant.

Grant Income

3 Months Ended

Mar. 31, 2022

(4) Grant Income

In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of buntanetap in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recognized grant income of $0 and $29,340 for the three months ended March 31, 2022 and 2021, respectively, in connection with the NIH grant. The Company received payments under the grant of $0 and $29,340 during the three months ended March 31, 2022 and 2021, respectively. The Company recorded a grant receivable of $0 as of March 31, 2022 and December 31, 2021, and had no unreimbursed, eligible costs incurred under the grant. As of March 31, 2022, there were no remaining funds available under the grant.